Characteristics of key patents covering recent FDA approved drugs

1 August 2022 - New drugs are protected by patents that block generic competition and allow manufacturers to charge high prices. ...

Read more →

EFPIA and Vaccines Europe are deeply disappointed about the decision taken by World Trade Organization at the Ministerial Conference to endorse a TRIPS waiver for COVID-19 vaccines

17 June 2022 - Speaking about the waiver, EFPIA Director General, Nathalie Moll said. “The decision is a serious retrograde step ...

Read more →

IP waiver for COVID vaccines is a threat to future innovation

20 June 2022 - The decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have ...

Read more →

IP waiver for COVID vaccines misses the mark in vaccinating the world

14 June 2022 - Vaccinating the world remains a priority and proposals to weaken the intellectual property for COVID-19 vaccines ...

Read more →

U.S. Senators ask regulators to clear drug patent 'thickets'

9 June 2022 - Letter asks U.S. Patent and Trademark Office to crack down on "highly similar" patents for single ...

Read more →

ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool

27 May 2022 - ViiV Healthcare and MPP are actively negotiating voluntary licensing terms to help widen access to innovative ...

Read more →

Understanding ‘evergreening’: making minor modifications of existing medications to extend protections

17 May 2022 - Recent studies have examined strategic behaviours in the pharmaceutical industry that extend patent and regulatory protection, known ...

Read more →

Pfizer settles two lawsuits, starts another over etanercept biosimilar in Australia

17 May 2022 - After agreeing to settle with Amgen over its oncology biosimilars, Pfizer issued a new patent lawsuit ...

Read more →

Leaked TRIPS proposal misguided about improving global COVID-19 vaccination rates

24 March 2022 - The leaked proposal on the waiver on intellectual property rights for COVID-19 vaccines is misguided and ...

Read more →

Catalyst Pharmaceuticals and KYE Pharmaceuticals announce a second favourable Canadian Federal Court ruling setting aside approval of Ruzurgi

11 March 2022 - Catalyst Pharmaceuticals and KYE Pharmaceuticals today announced receipt of a favourable decision from the Federal Court of ...

Read more →

Updating the Bayh-Dole Act; march-in rights and transparency

24 February 2022 - The Patent and Trademark Law Amendments Act (Bayh-Dole Act [35 USC §200-212]) was enacted in 1980 and ...

Read more →

MTAA welcomes patent box legislation

11 February 2022 - MTAA has welcomed the introduction of the Government’s Patent Box Bill into the House of Representatives ...

Read more →

Patent box legislation to promote Australian innovation

11 February 2022 - Medicines Australia notes the introduction of patent box legislation, Treasury Laws Amendment (Tax Concession for Australian ...

Read more →

Pfizer pushes to intervene in lawsuit seeking COVID vaccine information from FDA

27 January 2022 - Pfizer wants to intervene in a Texas federal lawsuit seeking information from the U.S. FDA used ...

Read more →

Patent thickets are thwarting U.S. availability of lower cost biosimilar medicines, study finds

18 January 2022 - Amid debate over competition in the pharmaceutical industry, a new analysis found just 6% of patents ...

Read more →